TYK2 inhibitors improved certain clinical measures of ulcerative colitis severity, like improved modified Mayo endoscopic and Mayo rectal bleeding sub-score in the intervention group; however, there was no strong evidence of effect on clinical remission. This evidence concerns the gene TYK2 and ulcerative colitis.